| Host: |
Goat |
| Applications: |
Pep-ELISA/WB |
| Reactivity: |
Human/Dog |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-RP11/PRPF31 (C-Term) is suitable for use in ELISA and Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
WB-0.3-1.0µg/mlELISA-antibody detection limit dilution 1:16000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
PRPF31 |
| Gene ID: |
26121 |
| Uniprot ID: |
PRP31_HUMAN |
| Immunogen Region: |
C-Term |
| Accession Number: |
NP_056444.3 |
| Immunogen Sequence: |
LKVKGEKSGLMST |
| Function | Involved in pre-mRNA splicing as component of the spliceosome. Required for the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome. |
| Protein Name | U4/U6 Small Nuclear Ribonucleoprotein Prp31Pre-Mrna-Processing Factor 31Serologically Defined Breast Cancer Antigen Ny-Br-99U4/U6 Snrnp 61 Kda ProteinProtein 61kHprp31 |
| Database Links | Reactome: R-HSA-72163 |
| Cellular Localisation | NucleusNucleus SpeckleCajal BodyPredominantly Found In Speckles And In Cajal Bodies |
| Alternative Antibody Names | Anti-U4/U6 Small Nuclear Ribonucleoprotein Prp31 antibodyAnti-Pre-Mrna-Processing Factor 31 antibodyAnti-Serologically Defined Breast Cancer Antigen Ny-Br-99 antibodyAnti-U4/U6 Snrnp 61 Kda Protein antibodyAnti-Protein 61k antibodyAnti-Hprp31 antibodyAnti-PRPF31 antibodyAnti-PRP31 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
